期刊簡介 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Molecular Therapy Nucleic Acids LetPub Score 7.4
51 ratings
Rate
Reputation 8.1 Influence 6.6 Speed 9.1 | ||||||||||||||||||||
期刊簡稱 | MOL THER NUCL ACIDS | ||||||||||||||||||||
ISSN | 2162-2531 | ||||||||||||||||||||
h-index | 43 | ||||||||||||||||||||
CiteScore |
| ||||||||||||||||||||
自引率 (2023-2024) | 1.50%自引率趨勢 | ||||||||||||||||||||
掲載範囲 |
| ||||||||||||||||||||
官方網站 | http://www.nature.com/mtna/index.html | ||||||||||||||||||||
在線稿件提交 | http://mts-mtna.nature.com/cgi-bin/main.plex | ||||||||||||||||||||
開放訪問 | Yes | ||||||||||||||||||||
出版商 | Cell Press | ||||||||||||||||||||
主題領域 | MEDICINE, RESEARCH & EXPERIMENTAL | ||||||||||||||||||||
出版國/地區 | UNITED STATES | ||||||||||||||||||||
發行頻率 | |||||||||||||||||||||
創刊年 | 0 | ||||||||||||||||||||
每年文章數 | 233每年文章數趨勢 | ||||||||||||||||||||
黃金OA百分比 | 90.82% | ||||||||||||||||||||
OA Related Info | APC: Yes( USD3900; ) APC waiver:Check Notes Other charges: No Keywords: vector development、rna based therapeutics、gene modifying agents Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review | ||||||||||||||||||||
Web of Science 四分位 ( 2023-2024) | WOS Quartile: Q1
| ||||||||||||||||||||
索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||
鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2162-2531%5BISSN%5D | ||||||||||||||||||||
平均審稿時間 * | 來自出版商的數據: 來自作者的數據: 20 Weeks | ||||||||||||||||||||
競爭力 * | 來自作者的數據: | ||||||||||||||||||||
參考鏈接 |
| ||||||||||||||||||||
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。 |
|
|
首頁 上一頁 1 2 3 4 5 6 7 下一頁 末頁 (頁 | |
[Molecular Therapy Nucleic Acids] 的評論 | 撰寫評論 |
作者: 碧桃幻露 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2024-04-17 19:26:08 評論於 3 points for distribution and 10 points for return, and it is still not a foul(0) 讚! | 碧桃幻露 |
作者: 魔都小柔 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-08-11 21:13:30 評論於 On July 18, 2023, the First Affiliated Hospital of Zhejiang University updated the "List of Journals Not Recommended for Submission". The hospital has set up a "List of Journals Not Recommended for Submission" based on the regularly published "International Journal Alert List" by the Chinese Academy of Sciences Literature and Information Center, and updates it dynamically. Starting from July 19, 2023, papers submitted to the following journals will not be reimbursed for page charges(0) 讚! | 魔都小柔 |
作者: 南风慕夏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-07-20 15:59:03 評論於 Hello, does this magazine require the upload of primary data?(0) 讚! | 南风慕夏 |
作者: 南风慕夏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-06-30 10:26:01 評論於 Is it possible to upload revised manuscripts after pre-acceptance?(0) 讚! | 南风慕夏 |
作者: 东京志燕 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-05-24 16:28:26 評論於 Review speed: 2.0 | Submission hit rate: 5.0 Experience sharing: After revising for 6 months and satisfying most reviewers' comments, the paper was rejected by a new foreign editor. It was a huge setback, everyone, run fast!(0) 讚! | 东京志燕 |
作者: 北海俊晤 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2023-05-07 21:41:46 評論於 Research focus: RNA; Cell biology experience sharing: Have you submitted any papers recently? I would like to know more about the review process and timeline. Thank you(0) 讚! | 北海俊晤 |
作者: luofeiyu 領域: 医学 審稿時間: 12.0 month(s) 結果: 直接被接受 撰寫評論 |
2023-01-03 11:59:02 評論於 These trash magazines have also been classified into Zone 1.(206) 讚! | luofeiyu |
作者: 烈焰以岚 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-27 22:08:32 評論於 The warning will be removed in the latest version this year... The quality of the articles published in the magazine recently is very good, showing clear progress(0) 讚! | 烈焰以岚 |
作者: 烈焰以岚 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-27 09:20:26 評論於 Congratulations(0) 讚! | 烈焰以岚 |
作者: 不灭心香 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-11 18:22:54 評論於 Review speed: 3.0 Emphasis on research direction: RNA Neuroscience Experience Sharing: Submitted on November 31, 2021, finally accepted on October 12, 2022, taking more than 11 months... The reviewers were very thorough and responsible, although most of the revisions were minor details, it was still very painful(0) 讚! | 不灭心香 |
作者: Sara Lincoln 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-10-10 15:55:31 評論於 This magazine has almost retracted all the articles from the paper factory. It is estimated that there will be no more warnings next year or the year after(0) 讚! | Sara Lincoln |
作者: Lucy Larkin 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-24 17:31:36 評論於 It is not surprising that this journal has been warned, as many articles produced by paper mills have been published in the past few years. However, there has been some improvement in the magazine this year(0) 讚! | Lucy Larkin |
作者: 震山今雨 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-09-19 08:15:25 評論於 This journal only has less than 3% self-citation, with less than 500 articles published each year, and the proportion of Chinese authors is not more than 25%. China's population accounts for 20% of the world's population, so what criteria should be used for early warning? If the warning is based solely on the proportion of Chinese authors, then what about the many domestic SCI journals with a 90% proportion? Why aren't they warned? What about other publishers who have many journals like Oncology Reports? Why aren't they warned?(0) 讚! | 震山今雨 |
作者: Sara Lincoln 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-30 22:36:13 評論於 Have you received it?(0) 讚! | Sara Lincoln |
作者: Sara Lincoln 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-06-30 20:11:49 評論於 Did you wrap up your article at the end?(0) 讚! | Sara Lincoln |
作者: 天神院志敏 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-15 23:20:07 評論於 The highly alert journal of the Chinese Academy of Sciences, there is no need to discuss(0) 讚! | 天神院志敏 |
作者: 虚徒之山 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-14 09:46:53 評論於 Review Speed: 6.0 | Submission Acceptance Rate: 25.0 Sharing Experience: I have been accepted by CAS, so I won't introduce it(0) 讚! | 虚徒之山 |
作者: 白云蕴秀 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-12 17:48:34 評論於 In the end, after spending four months with the editor for submission, one month for review, one month for minor revisions after receiving feedback, and two months for final review, the paper was finally accepted. Though the process was long, it ended with acceptance(0) 讚! | 白云蕴秀 |
作者: 不灭心香 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-09 17:34:04 評論於 Research focus: Molecular therapy; Neuro experience sharing: After the second review, it has been 1 and a half months and the decision has been in process for 2 days. Does this mean the paper is going to be rejected?(0) 讚! | 不灭心香 |
作者: 霹雳鸿光 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-04-05 10:41:23 評論於 Submitting Falsified Data to Chinese Journals(0) 讚! | 霹雳鸿光 |
作者: Quinn Pullan 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-02-11 11:45:55 評論於 Garbage(0) 讚! | Quinn Pullan |
作者: 平原代芹 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-02-09 18:19:22 評論於 Review Speed: 2.0 | Submission Acceptance Rate: 25.0 Experience Sharing: Very slow, typically takes over 9 months(0) 讚! | 平原代芹 |
作者: 平原代芹 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-02-09 13:49:42 評論於 That's you, not mine(0) 讚! | 平原代芹 |
作者: 深渊绍辉 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-27 15:14:27 評論於 oncology reports like this are still unpredictable. This warning list is just silly(0) 讚! | 深渊绍辉 |
作者: 明冠文成 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定&不明 撰寫評論 |
2022-01-21 15:27:42 評論於 I'll be back in about two weeks(0) 讚! | 明冠文成 |
首頁 上一頁 1 2 3 4 5 6 7 下一頁 末頁 (頁 |
Contact us